Publications

The Consumer Product Safety Commission should shift more enforcement focus toward Chinese e-commerce platforms—like Temu and SHEIN—because, despite widespread safety violations linked to Chinese-made goods, these high-scale marketplaces face disproportionately little scrutiny despite posing significant risks to U.S. consumers.

EU regulators have targeted U.S. tech firms for years, demanding digital sovereignty, stronger consumer protections, platform openness, and structural remedies for dominance. The United States should apply that same logic to “Big Spread”—Nutella’s market power warrants investigation, regulation, and potential breakup.

Canada is considering banning social media for teenagers, but the evidence suggests this approach is misplaced. Harm is not driven by access alone, but by specific online experiences, and a blanket ban would do little to address them.

America’s Living Library Act would turn U.S. biodiversity into a strategic innovation asset by fueling AI-enabled drug discovery, strengthening biopharma R&D, and helping America stay ahead in the global biotech race.

Virginia’s one-hour social media limit for minors is a misguided policy that undermines parental authority, raises constitutional concerns, and fails to effectively address the real drivers of youth online harm.

“Emergency” legislation like the Sanders-Ocasio-Cortez AI Data Center Moratorium Act is not necessary to protect Americans from rate increases. Concerns about energy and data centers are misplaced, and there are plenty of options to ensure a smooth path to growth.

If the policy framework is right, AI infrastructure can strengthen the electricity grid rather than strain it, stabilize prices rather than inflate them, and transform heat and flexible demand into system assets.

Sales of Chinese hybrids and plug-in hybrids in Europe increased by a factor of 14 between August 2024 and August 2025

Countries in the Global South are key markets for Chinese and U.S.-allied national power industries, which require scale economies to flourish. U.S. policymakers should stop viewing them as a “backyard” and recognize that they are a key battlefield in an industrial war.

The Trump administration’s Section 232 pharmaceutical tariffs will needlessly raise drug costs, harm U.S. patients, and undermine both domestic manufacturing and global biopharmaceutical innovation, while better policy options exist to strengthen the industry without these damaging side effects.